NCT04610359View on ClinicalTrials.gov

Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis

PHASE1UnknownINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Interstitial CystitisStem Cell TransplantMesenchymal Stem Cell
Interventions
DRUG

MR-MC-01

Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)

Trial Locations (1)

138-736

RECRUITING

Department of Urology, Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

MIRAE CELL BIO

UNKNOWN

lead

Asan Medical Center

OTHER